<DOC>
	<DOCNO>NCT00106600</DOCNO>
	<brief_summary>The goal study find safe dose Pixantrone ( BBR 2778 ) give patient Acute Myelogenous Leukemia ( AML ) . After safe dose find , additional 86 patient enrolled . During part study , safety effectiveness evaluate .</brief_summary>
	<brief_title>Pixantrone ( BBR 2778 ) Patients With Refractory Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>This open label , single center , phase I/II study pixantrone patient refractory AML . Pixantrone administer three consecutive day day 1 , 2 3 21-day cycle , two cycle . The study 2 part ; phase I phase II . In phase I part study , maximum tolerate dose ( MTD ) pixantrone single agent patient refractory AML determine . In phase II part study , additional 86 patient treat MTD assess disease response .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<criteria>Patients morphologically confirm diagnosis relapse AML FrenchAmericanBritish ( FAB ) classification M3 . Relapse demonstrate presence great 5 % leukemic blast bone marrow reappearance great 5 % leukemic blast peripheral blood within 14 day registration . Eligible patient include follow : Patients secondary AML , include patient prior myelodysplastic syndrome ( MDS ) Patients initially unresponsive induction therapy Patients first second relapse prior therapy hematopoietic stemcell transplant ( HSCT ) A period least 21 day must elapse completion prior chemotherapy ( without anthracyclines ) investigational agent first dose treatment study , acute toxicity prior therapy must resolve ( exception alopecia ) . Age &gt; /= 18 year age , able give inform consent . ECOG performance status 0 , 1 2 . Bilirubin &lt; 1.5 x institution 's upper limit normal ( ULN ) , AST ALT &lt; 1.5 x institution 's ULN , creatinine &lt; 2 mg/dL . LVEF &gt; /= 50 % measure MUGA scan 2D ECHO within 14 day prior registration . Either method acceptable measure LVEF ; however , method must use throughout treatment followup . Patients ( male female ) reproductive potential must commit use adequate contraception ( defined investigator ) study treatment 6 month last day study drug administration . Patients must sign approve informed consent prior begin protocol specific procedure Prior treatment cumulative dose doxorubicin equivalent exceed 450 mg/m2 accord follow calculation index : X/450 + Y/160 &lt; 1 X doxorubicin dose mg/m2 Y mitoxantrone dose mg/m2 . Clinical documented central nervous system ( CNS ) involvement AML . Any uncontrolled active infection require antibiotic . History Human Immunodeficiency Virus ( HIV ) . Acute hepatitis , know chronic hepatitis . Unstable cardiovascular condition , include : cardiac arrhythmia , angina , myocardial infarction within past 6 month . Pregnant woman nurse mother . Prior malignancy except : curatively treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently remission , cancer patient diseasefree 5 year . Any condition , judgment investigator , would place patient undue risk , interfere result study , make patient otherwise unsuitable . Any circumstance time study entry would preclude completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>